Cybin Inc’s Post

**GLP-1 AGONISTS & ALCOHOL USE?** Anecdotally, such a high number of my patients on GLP-1 agonists report not having much of a desire to drink alcohol anymore. And they are not bothered by this. My hope is that several pharmaceutical companies are actively researching this. Our patients with alcohol use disorder deserve more FDA approved, insurance covered treatment options. There is currently one The National Institute on Drug Abuse (NIDA) phase 2 clinical trial recruiting patients - Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial: https://lnkd.in/eAhBQyRt #alcoholusedisorder #research #ozempic #semaglutide #clinicaltrials

High dose of SSRI for OCD (650 mg Sertraline, 80 mg Escitalopram, 120 mg Fluoxetine, 600 mg Fluvoxamine)

First long-term study confirms feasibility of high-dose SSRIs in #OCD: https://lnkd.in/egamR6q4 Doses went up to 650mg sertraline, 80mg escitalopram, 120mg fluoxetine, 600mg fluvoxamine. The study lasted 21 months, but had flaws in design (retrospective, only 105 subjects). I have seen distinct responses above the FDA limit in OCD, but have never gone to the maximums reported here. #psychiatry

Is mild cognitive impairment associated with less reflective, more intuitive decisions? Jeff Zemla found that it was in a sample of people from the #Alzheimers Prevention Registry (N = 93): https://lnkd.in/e2iup6vG Interesting implications for #cognitiveDecline# research and #policy. #psychiatry #clinicalPsychology #decisionScience #medicine

#Is_it_better_to_maintain_or_reduce? When treating a patient with a longstanding history of schizophrenia on long-term antipsychotic polypharmacy, you may hesitate to reduce the treatment but also consider minimizing it. The key question: is it better to maintain or reduce? A recent study sheds light on this by examining the effects of switching from antipsychotic polypharmacy (APP) to monotherapy (APM). Results showed that patients on long-term polypharmacy experienced significant reductions in movement disorders, metabolic issues, and certain side effects after switching to monotherapy. This offers valuable insight for optimizing treatment. Read more here :

If you're looking for resources to support your treatment planning for mental health patients, SwitchRx provides healthcare professionals with the most current and useful information to guide their clinical practice when adjusting their patient's psychotropic treatment regimens. You'll find resources suggesting tapering and titration schedules, clinical tips, detailed info on drug pharmacokinetics, and other precautions. It's free: https://lnkd.in/exZxk_E2 #MentalHealthSupport #Pharmacokinetics #Psychiatry

From #IM2024: In this interview at the American College of Physicians annual meeting, Sejal Shah, MD, of Brigham and Women's Hospital and Harvard Medical School, discusses key considerations for managing individuals with acute psychiatric diagnoses in the inpatient setting. Full interview: https://lnkd.in/gpe_V5V6 #Psychiatry

Are you conducting groundbreaking research in the fields of psychiatric disorders, cognitive disorders, or epilepsy? 🌍 Share your findings with the world at #eINS2025 in Istanbul! Your insights could pave the way for future treatments and shape the future of neurological healthcare. 👉 Submit your abstract today: https://bit.ly/4evMbDp #eINS2025 #Psychiatry #CognitiveDisorders #Epilepsy #Neuromodulation

Knowing is power.

Most #depression guidelines fail to discuss the long-term metabolic and tardive dyskinesia risks with antipsychotics, despite endorsing them for antidepressant augmentation, concludes letter in AJP by H Kavirajan: https://lnkd.in/e4_RBmcn Guidelines with less pharma influence were more restrained in their endorsements. ------------------------------------------ Learn more in the April edition of Carlat #Psychiatry News: https://lnkd.in/es9s3KdU